$45.09
+0.34 (+0.76%)
Open$44.83
Previous Close$44.75
Day High$45.57
Day Low$44.35
52W High$49.32
52W Low$28.95
Volume—
Avg Volume494.7K
Market Cap2.29B
P/E Ratio94.61
EPS$0.42
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
-3.3% upside
Current
$45.09
$45.09
Target
$43.60
$43.60
$27.22
$43.60 avg
$49.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 264.12M | 222.15M | 156.14M |
| Net Income | 15.79M | 11.95M | 35.53M |
| Profit Margin | 6.0% | 5.7% | 22.8% |
| EBITDA | 21.59M | 17.25M | 44.60M |
| Free Cash Flow | — | — | 32.60M |
| Rev Growth | +18.9% | +18.9% | +24.7% |
| Debt/Equity | 0.01 | 0.01 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |